NYSE:NVTA - Invitae Stock Price, Price Target & More

$5.62 +0.03 (+0.54 %)
(As of 04/24/2018 12:42 PM ET)
Previous Close$5.59
Today's Range$5.5850 - $5.75
52-Week Range$4.35 - $10.41
Volume172,228 shs
Average Volume947,824 shs
Market Capitalization$302.32 million
P/E Ratio-2.12
Dividend YieldN/A
Beta1.07

About Invitae (NYSE:NVTA)

Invitae logoInvitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It also operates Patient Insights Networks, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform that is used for the collection, analysis, and management of patient family history information. Invitae Corporation serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.

Receive NVTA News and Ratings via Email

Sign-up to receive the latest news and ratings for NVTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVTA
CUSIPN/A
Phone415-374-7782

Debt

Debt-to-Equity Ratio0.35%
Current Ratio2.60%
Quick Ratio2.60%

Price-To-Earnings

Trailing P/E Ratio-2.12
Forward P/E Ratio-2.52
P/E GrowthN/A

Sales & Book Value

Annual Sales$68.22 million
Price / Sales4.36
Cash FlowN/A
Price / CashN/A
Book Value$2.30 per share
Price / Book2.44

Profitability

EPS (Most Recent Fiscal Year)($2.65)
Net Income$-123,380,000.00
Net Margins-180.85%
Return on Equity-124.43%
Return on Assets-68.92%

Miscellaneous

Employees594
Outstanding Shares52,940,000

How to Become a New Pot Stock Millionaire

Invitae (NYSE:NVTA) Frequently Asked Questions

What is Invitae's stock symbol?

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) posted its quarterly earnings results on Monday, February, 12th. The medical research company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.61) by $0.17. The medical research company had revenue of $25.40 million for the quarter, compared to analyst estimates of $24.18 million. Invitae had a negative return on equity of 124.43% and a negative net margin of 180.85%. The firm's revenue for the quarter was up 175.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.69) EPS. View Invitae's Earnings History.

When is Invitae's next earnings date?

Invitae is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for Invitae.

What price target have analysts set for NVTA?

4 Wall Street analysts have issued 12 month price targets for Invitae's shares. Their predictions range from $9.00 to $15.00. On average, they expect Invitae's share price to reach $11.00 in the next twelve months. View Analyst Ratings for Invitae.

Who are some of Invitae's key competitors?

Who are Invitae's key executives?

Invitae's management team includes the folowing people:
  • Dr. Randal W. Scott, Exec. Chairman (Age 60)
  • Dr. Sean E. George, Co-Founder, Pres, CEO & Director (Age 44)
  • Dr. Robert L. Nussbaum, Chief Medical Officer (Age 68)
  • Ms. Shelly D. Guyer, Chief Financial Officer (Age 58)
  • Mr. Lee Bendekgey, Chief Operating Officer (Age 60)

When did Invitae IPO?

(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

Has Invitae been receiving favorable news coverage?

News articles about NVTA stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Invitae earned a coverage optimism score of 0.09 on Accern's scale. They also gave media coverage about the medical research company an impact score of 47.17 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Invitae's major shareholders?

Invitae's stock is owned by many different of retail and institutional investors. Top institutional investors include WELLINGTON MANAGEMENT PORTFOLIOS (DUBLIN) PUBLIC LTD COMPANY (5.23%). Company insiders that own Invitae stock include Bros Advisors Lp Baker, E Lee Bendekgey, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum and Thomas Brida. View Institutional Ownership Trends for Invitae.

How do I buy shares of Invitae?

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Invitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $5.64.

How big of a company is Invitae?

Invitae has a market capitalization of $302.32 million and generates $68.22 million in revenue each year. The medical research company earns $-123,380,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. Invitae employs 594 workers across the globe.

How can I contact Invitae?

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]


MarketBeat Community Rating for Invitae (NVTA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  179 (Vote Underperform)
Total Votes:  338
MarketBeat's community ratings are surveys of what our community members think about Invitae and other stocks. Vote "Outperform" if you believe NVTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Invitae (NYSE:NVTA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Invitae in the last 12 months. Their average twelve-month price target is $11.00, suggesting that the stock has a possible upside of 95.73%. The high price target for NVTA is $15.00 and the low price target for NVTA is $9.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.00$11.00$12.75$14.3333
Price Target Upside: 95.73% upside90.97% upside68.21% upside55.46% upside

Invitae (NYSE:NVTA) Consensus Price Target History

Price Target History for Invitae (NYSE:NVTA)

Invitae (NYSE:NVTA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/13/2018JPMorgan ChaseLower Price TargetOverweight -> Overweight$13.00 -> $9.00HighView Rating Details
2/13/2018BenchmarkLower Price TargetBuy -> Buy$11.00 -> $10.00HighView Rating Details
1/16/2018Leerink SwannLower Price TargetOutperform -> Outperform$12.00 -> $10.00HighView Rating Details
1/5/2018Ladenburg ThalmannInitiated CoverageBuy -> Buy$15.00HighView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Invitae (NYSE:NVTA) Earnings History and Estimates Chart

Earnings by Quarter for Invitae (NYSE:NVTA)

Invitae (NYSE:NVTA) Earnings Estimates

2018 EPS Consensus Estimate: ($2.20)
2019 EPS Consensus Estimate: ($1.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.63)($0.59)($0.61)
Q2 20182($0.63)($0.53)($0.58)
Q3 20182($0.60)($0.47)($0.54)
Q4 20182($0.53)($0.41)($0.47)
Q1 20192($0.57)($0.37)($0.47)
Q2 20192($0.52)($0.33)($0.43)
Q3 20192($0.45)($0.29)($0.37)
Q4 20192($0.35)($0.23)($0.29)

Invitae (NYSE NVTA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018        
2/12/2018Q4 2017($0.61)($0.78)$24.18 million$25.40 millionViewListenView Earnings Details
11/6/2017Q3 2017($0.55)($0.57)$20.59 million$18.15 millionViewN/AView Earnings Details
8/7/20176/30/2017($0.64)($0.66)$13.31 million$14.34 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.68)($0.64)$10.90 million$10.34 millionViewListenView Earnings Details
2/13/2017Q416($0.73)($0.69)$8.82 million$9.20 millionViewN/AView Earnings Details
11/7/2016Q316($0.72)($0.77)$7.50 million$6.30 millionViewListenView Earnings Details
8/8/2016Q216($0.76)($0.77)$5.81 million$5.60 millionViewN/AView Earnings Details
5/9/2016Q116($0.76)($0.80)$4.38 million$4.00 millionViewN/AView Earnings Details
2/9/2016Q415($0.72)($0.76)$2.92 million$3.20 millionViewN/AView Earnings Details
11/5/2015Q315($0.70)($0.71)$2.55 million$2.19 millionViewN/AView Earnings Details
8/6/2015Q215($0.55)($0.76)$1.67 million$1.80 millionViewN/AView Earnings Details
5/12/2015Q115($0.51)($1.09)$1.07 million$1.23 millionViewListenView Earnings Details
3/10/2015Q4 2014($16.75)$0.88 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Invitae (NYSE:NVTA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Invitae (NYSE NVTA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.70%
Institutional Ownership Percentage: 71.41%
Insider Trading History for Invitae (NYSE:NVTA)
Institutional Ownership by Quarter for Invitae (NYSE:NVTA)

Invitae (NYSE NVTA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2018Randal W ScottInsiderBuy44,444$4.50$199,998.00View SEC Filing  
3/28/2018Bros. Advisors Lp BakerMajor ShareholderBuy1,111,111$4.50$4,999,999.50View SEC Filing  
10/10/2017Patty DumondVPSell2,497$10.00$24,970.00View SEC Filing  
10/9/2017Patty DumondVPSell1,882$10.00$18,820.0052,783View SEC Filing  
9/12/2017Katherine StuelandInsiderSell612$9.40$5,752.8058,570View SEC Filing  
2/16/2017Thomas BridaGeneral CounselSell766$9.69$7,422.5424,720View SEC Filing  
2/15/2017E Lee BendekgeyCFOSell2,098$9.59$20,119.8260,882View SEC Filing  
2/15/2017Patty DumondVPSell1,264$9.55$12,071.2055,929View SEC Filing  
2/15/2017Robert L NussbaumInsiderSell1,686$9.53$16,067.5862,823View SEC Filing  
2/15/2017Thomas BridaGeneral CounselSell794$9.54$7,574.7626,280View SEC Filing  
11/22/2016Randal W ScottChairmanBuy66,666$6.00$399,996.003,506,225View SEC Filing  
11/18/2016Geoffrey CrouseDirectorBuy15,000$6.25$93,750.0034,259View SEC Filing  
11/17/2016Bros. Advisors Lp BakerMajor ShareholderBuy733,333$6.00$4,399,998.00View SEC Filing  
9/16/2016Patty DumondVPSell1,000$8.00$8,000.009,812View SEC Filing  
8/15/2016Patty DumondVPSell1,000$8.81$8,810.009,812View SEC Filing  
7/14/2016Patty DumondVPSell1,000$8.79$8,790.009,812View SEC Filing  
6/16/2016Patty DumondVPSell1,000$8.00$8,000.009,812View SEC Filing  
5/17/2016Patty DumondVPSell3,221$8.47$27,281.8712,033View SEC Filing  
4/14/2016Patty DumondVPSell1,000$10.50$10,500.009,812View SEC Filing  
2/22/2016Lisa AldersonInsiderSell7,500$7.64$57,300.0031,819View SEC Filing  
2/11/2016Sean E GeorgeCOOBuy16,950$6.16$104,412.00235,408View SEC Filing  
2/18/2015James E FlynnInsiderBuy175,000$16.00$2,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Invitae (NYSE NVTA) News Headlines

Source:
DateHeadline
Invitae Co. (NVTA) Expected to Announce Earnings of -$0.64 Per ShareInvitae Co. (NVTA) Expected to Announce Earnings of -$0.64 Per Share
www.americanbankingnews.com - April 24 at 3:20 AM
Comparing Invitae (NVTA) and Its RivalsComparing Invitae (NVTA) and Its Rivals
www.americanbankingnews.com - April 21 at 1:04 AM
Invitae (NVTA) Raised to "Strong-Buy" at Zacks Investment ResearchInvitae (NVTA) Raised to "Strong-Buy" at Zacks Investment Research
www.americanbankingnews.com - April 18 at 10:04 AM
Financial Review: Invitae (NVTA) vs. Its RivalsFinancial Review: Invitae (NVTA) vs. Its Rivals
www.americanbankingnews.com - April 17 at 11:10 PM
Zacks Investment Research Downgrades Invitae (NVTA) to SellZacks Investment Research Downgrades Invitae (NVTA) to Sell
www.americanbankingnews.com - April 17 at 9:15 PM
Invitae (NVTA) vs. Its Competitors Financial SurveyInvitae (NVTA) vs. Its Competitors Financial Survey
www.americanbankingnews.com - April 16 at 7:15 AM
Invitae Co. (NVTA) Given Consensus Rating of "Hold" by BrokeragesInvitae Co. (NVTA) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 15 at 1:27 PM
Invitae (NVTA) Cut to Sell at BidaskClubInvitae (NVTA) Cut to Sell at BidaskClub
www.americanbankingnews.com - April 15 at 12:35 PM
Invitae (NVTA) and Its Peers Head-To-Head ContrastInvitae (NVTA) and Its Peers Head-To-Head Contrast
www.americanbankingnews.com - April 14 at 7:43 AM
BidaskClub Upgrades Invitae (NVTA) to "Hold"BidaskClub Upgrades Invitae (NVTA) to "Hold"
www.americanbankingnews.com - April 13 at 4:23 PM
Analyzing Invitae (NVTA) & Its CompetitorsAnalyzing Invitae (NVTA) & Its Competitors
www.americanbankingnews.com - April 13 at 8:53 AM
Head to Head Analysis: Invitae (NVTA) & Its PeersHead to Head Analysis: Invitae (NVTA) & Its Peers
www.americanbankingnews.com - April 13 at 1:07 AM
Financial Comparison: Invitae (NVTA) versus The CompetitionFinancial Comparison: Invitae (NVTA) versus The Competition
www.americanbankingnews.com - April 11 at 9:20 PM
Invitae (NVTA) Rating Lowered to Sell at Zacks Investment ResearchInvitae (NVTA) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 11 at 9:27 AM
Invitae (NVTA) Stock Rating Upgraded by Zacks Investment ResearchInvitae (NVTA) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 10 at 7:17 PM
Invitae research highlights utility of proactive genetic screening, importance of assessing secondary findings in genetic ...Invitae research highlights utility of proactive genetic screening, importance of assessing secondary findings in genetic ...
www.prnewswire.com - April 10 at 4:49 PM
Invitae (NVTA) & Its Peers Head to Head SurveyInvitae (NVTA) & Its Peers Head to Head Survey
www.americanbankingnews.com - April 9 at 5:13 AM
Invitae Co. (NVTA) Expected to Post Quarterly Sales of $25.82 MillionInvitae Co. (NVTA) Expected to Post Quarterly Sales of $25.82 Million
www.americanbankingnews.com - April 9 at 4:06 AM
BidaskClub Upgrades Invitae (NVTA) to HoldBidaskClub Upgrades Invitae (NVTA) to Hold
www.americanbankingnews.com - April 8 at 9:07 AM
Genomic Health (GHDX) and Invitae (NVTA) Head-To-Head ReviewGenomic Health (GHDX) and Invitae (NVTA) Head-To-Head Review
www.americanbankingnews.com - April 7 at 3:16 PM
Invitae (NVTA) and Its Rivals Critical ComparisonInvitae (NVTA) and Its Rivals Critical Comparison
www.americanbankingnews.com - April 7 at 7:31 AM
Zacks: Brokerages Expect Invitae Co. (NVTA) Will Announce Earnings of -$0.64 Per ShareZacks: Brokerages Expect Invitae Co. (NVTA) Will Announce Earnings of -$0.64 Per Share
www.americanbankingnews.com - April 7 at 5:58 AM
Zacks Investment Research Downgrades Invitae (NVTA) to HoldZacks Investment Research Downgrades Invitae (NVTA) to Hold
www.americanbankingnews.com - April 7 at 12:39 AM
Critical Review: ELEKTA (EKTAY) vs. Invitae (NVTA)Critical Review: ELEKTA (EKTAY) vs. Invitae (NVTA)
www.americanbankingnews.com - April 5 at 9:18 AM
Invitae (NVTA) Rating Lowered to Hold at BidaskClubInvitae (NVTA) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - April 4 at 11:58 PM
Invitae (NVTA) and Its Competitors Financial SurveyInvitae (NVTA) and Its Competitors Financial Survey
www.americanbankingnews.com - April 4 at 11:12 PM
Critical Review: InVitae (NVTA) & The CompetitionCritical Review: InVitae (NVTA) & The Competition
www.americanbankingnews.com - April 3 at 9:23 PM
InVitae Corp (NVTA) Insider Randal W. Scott Acquires 44,444 SharesInVitae Corp (NVTA) Insider Randal W. Scott Acquires 44,444 Shares
www.americanbankingnews.com - April 2 at 10:20 PM
BidaskClub Lowers InVitae (NVTA) to SellBidaskClub Lowers InVitae (NVTA) to Sell
www.americanbankingnews.com - April 2 at 10:13 AM
Form 4 BAKER FELIX For: Mar 28 Filed by: Invitae CorpForm 4 BAKER FELIX For: Mar 28 Filed by: Invitae Corp
www.streetinsider.com - March 31 at 8:56 AM
InVitae Corp (NVTA) Major Shareholder Bros. Advisors Lp Baker Acquires 1,111,111 SharesInVitae Corp (NVTA) Major Shareholder Bros. Advisors Lp Baker Acquires 1,111,111 Shares
www.americanbankingnews.com - March 29 at 4:20 PM
Heres Why Invitae Stock Dropped as Much as 19.6% TodayHere's Why Invitae Stock Dropped as Much as 19.6% Today
www.fool.com - March 29 at 9:20 AM
Here's Why Invitae Stock Dropped as Much as 19.6% TodayHere's Why Invitae Stock Dropped as Much as 19.6% Today
finance.yahoo.com - March 28 at 4:46 PM
Mid-Afternoon Market Update: NASDAQ Down Over 100 Points; Invitae Shares Fall Following Announcement Of $50M ...Mid-Afternoon Market Update: NASDAQ Down Over 100 Points; Invitae Shares Fall Following Announcement Of $50M ...
www.nasdaq.com - March 27 at 4:55 PM
This Explains Why Invitae Is Sinking TodayThis Explains Why Invitae Is Sinking Today
finance.yahoo.com - March 27 at 4:55 PM
Invitae Corporation (NYSE:NVTA): When Will It Breakeven?Invitae Corporation (NYSE:NVTA): When Will It Breakeven?
finance.yahoo.com - March 27 at 4:55 PM
10 Stocks To Watch For March 27, 201810 Stocks To Watch For March 27, 2018
www.benzinga.com - March 27 at 8:56 AM
Zacks: Brokerages Anticipate InVitae Corp (NVTA) Will Post Quarterly Sales of $25.82 MillionZacks: Brokerages Anticipate InVitae Corp (NVTA) Will Post Quarterly Sales of $25.82 Million
www.americanbankingnews.com - March 23 at 8:28 AM
Invitae expands network of patients in rare and ultra-rare diseasesInvitae expands network of patients in rare and ultra-rare diseases
finance.yahoo.com - March 22 at 9:06 AM
InVitae Corp (NVTA) Given Consensus Recommendation of "Hold" by AnalystsInVitae Corp (NVTA) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 21 at 3:56 PM
Zacks: Analysts Expect InVitae Corp (NVTA) to Post -$0.64 Earnings Per ShareZacks: Analysts Expect InVitae Corp (NVTA) to Post -$0.64 Earnings Per Share
www.americanbankingnews.com - March 21 at 5:18 AM
Invitae partners with KEW, Inc. to develop somatic mutation detection capabilities to improve cancer care by providing comprehensive genomic informationInvitae partners with KEW, Inc. to develop somatic mutation detection capabilities to improve cancer care by providing comprehensive genomic information
finance.yahoo.com - March 16 at 9:50 AM
BRIEF-Invitae Says Goal Of 1 Mln Customers, $500 Mln In Revenue In 2020BRIEF-Invitae Says Goal Of 1 Mln Customers, $500 Mln In Revenue In 2020
www.reuters.com - March 13 at 10:41 AM
Technical Perspectives on Medical Research Stocks -- Bruker, DexCom, Invitae, and IQVIATechnical Perspectives on Medical Research Stocks -- Bruker, DexCom, Invitae, and IQVIA
www.bizjournals.com - March 7 at 9:37 AM
What Are Analysts Saying About Invitae Corporation’s (NYSE:NVTA) Future?What Are Analysts Saying About Invitae Corporation’s (NYSE:NVTA) Future?
finance.yahoo.com - March 6 at 4:47 PM
$25.82 Million in Sales Expected for InVitae Corp (NVTA) This Quarter$25.82 Million in Sales Expected for InVitae Corp (NVTA) This Quarter
www.americanbankingnews.com - March 6 at 10:47 AM
Invitae expands existing credit facility to provide up to $40.0 million in available growth capitalInvitae expands existing credit facility to provide up to $40.0 million in available growth capital
finance.yahoo.com - February 27 at 4:55 PM
Invitae to present at the Cowen and Company 38th Annual Health Care ConferenceInvitae to present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - February 26 at 9:25 AM
ARK Investment Management LLC Buys 643,860 Shares of InVitae Corp (NVTA)ARK Investment Management LLC Buys 643,860 Shares of InVitae Corp (NVTA)
www.americanbankingnews.com - February 26 at 5:12 AM
InVitae Corp (NVTA) Receives Average Recommendation of "Hold" from AnalystsInVitae Corp (NVTA) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 24 at 3:42 PM

SEC Filings

Invitae (NYSE:NVTA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Invitae (NYSE:NVTA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Invitae (NYSE NVTA) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.